RESUMEN
The efficacy of pharmacological disruption of fear memory reconsolidation depends on several factors, including memory strength and age. We built on previous observations that systemic treatment with the nootropic nefiracetam potentiates cued fear memory destabilization to facilitate mifepristone-induced reconsolidation impairment. Here, we applied nefiratecam and mifepristone to strongly conditioned, 1-wk-old contextual fear memories in male rats. Unexpectedly, the combined treatment did not result in impairment of contextual fear expression. However, mifepristone did reduce freezing to a novel context. These observations suggest that strong and established contextual fear memories do undergo destabilization without the need for pharmacological facilitation, and that impairments in strong context fear memory reconsolidation can manifest as a reduction in generalization.
Asunto(s)
Miedo/efectos de los fármacos , Generalización Psicológica/efectos de los fármacos , Memoria/efectos de los fármacos , Mifepristona/toxicidad , Nootrópicos/toxicidad , Animales , Condicionamiento Psicológico/efectos de los fármacos , Extinción Psicológica , Reacción Cataléptica de Congelación , Masculino , Pirrolidinonas/farmacología , RatasRESUMEN
A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Butirilcolinesterasa/metabolismo , Inhibidores de la Colinesterasa/uso terapéutico , Nootrópicos/uso terapéutico , Triptófano/análogos & derivados , Triptófano/uso terapéutico , Animales , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/toxicidad , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Ratones , Estructura Molecular , Nootrópicos/síntesis química , Nootrópicos/toxicidad , Relación Estructura-Actividad , Triptófano/toxicidadRESUMEN
Nobiletin and tangeretin are major components of polymethoxylated flavones in the peels of citrus fruits such as Citrus reticulata. Because nobiletin and tangeretin have attracted attention due to their beneficial health properties, citrus peel extracts, in which they are concentrated, have the potential to serve as a functional food ingredient to prevent diseases. In this study, a series of toxicological studies on the peel extract of Ponkan cultivar 'Ohta ponkan' (Citrus reticulata Blanco), was conducted. No mutagenic activity was observed in a bacterial reverse mutation test, whereas chromosomal aberrations were induced in an in vitro mammalian chromosomal aberration test. No genotoxicity was observed in an in vivo mammalian micronucleus test. In a 90-day study at daily doses of 54, 180, or 540 mg/kg body weight (bw)/day, hyaline droplet nephropathy, which specifically occurs in adult male rats, was observed in males of 540 mg/kg bw/day group. No other adverse effects were observed in the 90-day study. The no adverse effect level in the 90-day study was considered to be 540 mg/kg bw/day for female rats and less than 540 mg/kg bw/day for male rats.
Asunto(s)
Citrus/química , Flavonas/toxicidad , Nootrópicos/toxicidad , Extractos Vegetales/toxicidad , Plantas Medicinales/toxicidad , Administración Oral , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Peso Corporal/efectos de los fármacos , Aberraciones Cromosómicas/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Flavonas/administración & dosificación , Flavonas/química , Alimentos Funcionales/efectos adversos , Alimentos Funcionales/toxicidad , Masculino , Pruebas de Micronúcleos , Nootrópicos/administración & dosificación , Nootrópicos/química , Enfermedad de Parkinson/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Plantas Medicinales/química , Ratas , Ratas Sprague-DawleyRESUMEN
The immunoproteasome (iP), an inducible proteasome variant harboring three immunosubunits, low molecular mass polypeptide-2 (LMP2), multicatalytic endopeptidase complex subunit-1, and low molecular mass polypeptide-7 (LMP7), is involved in multiple facets of inflammatory responses. We recently reported that YU102, a dual inhibitor of the iP subunit LMP2 and the constitutive proteasome catalytic subunit ß1, ameliorates cognitive impairments in mouse models of Alzheimer's disease (AD) independently of amyloid deposits. To investigate whether inhibition of LMP2 is sufficient to improve the cognitive functions of AD mice, here we prepared 37 YU102 analogues and identified a potent LMP2 inhibitor DB-310 (28) (IC50: 80.6 nM) with improved selectivity and permeability in cells overexpressing ABCB1 transporters. We show that DB-310 induces suppression of IL-1α production in microglia cells and improves cognitive functions in the Tg2576 transgenic mouse model of AD. This study supports that inhibition of LMP2 is a promising therapeutic strategy for treatment of AD.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/uso terapéutico , Nootrópicos/uso terapéutico , Oligopéptidos/uso terapéutico , Animales , Línea Celular Transformada , Inhibidores de Cisteína Proteinasa/síntesis química , Inhibidores de Cisteína Proteinasa/toxicidad , Transición Epitelial-Mesenquimal/efectos de los fármacos , Humanos , Interleucina-1alfa/metabolismo , Ratones Transgénicos , Microglía/efectos de los fármacos , Estructura Molecular , Nootrópicos/síntesis química , Nootrópicos/toxicidad , Oligopéptidos/síntesis química , Oligopéptidos/toxicidad , Bibliotecas de Moléculas Pequeñas/síntesis química , Bibliotecas de Moléculas Pequeñas/uso terapéutico , Bibliotecas de Moléculas Pequeñas/toxicidad , Relación Estructura-ActividadRESUMEN
Cinnabar is an attractive mineral with many different uses. It is reported that cinnabar is one of the traditional Chinese's medicines extensively use. The main objective of this critical review is to identify the current overview, concept and chemistry of cinnabar, which includes the process developments, challenges, and diverse options for pharmacology research. It is used as a medicine through probable toxicity, especially when taking overdoes. This review is the first to describe the toxicological effects of cinnabar and its associated compounds. Nuclear magnetic resonance (NMR) dependent metabolomics could be useful for examination of the pharmaceutical consequence. The analysis indicated that the accurate preparation methods, appropriate doses, disease status, ages with drug combinations are significant factors for impacting the cinnabar toxicity. Toxicologically, synthetic mercury sulfide or cinnabar should be notable for mercuric chloride, mercury vapor and methyl mercury for future protection and need several prominent advancements in cinnabar research.
Asunto(s)
Amnesia/tratamiento farmacológico , Hipnóticos y Sedantes/uso terapéutico , Compuestos de Mercurio/uso terapéutico , Nootrópicos/uso terapéutico , Agitación Psicomotora/tratamiento farmacológico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/patología , Amnesia/fisiopatología , Animales , Cálculo de Dosificación de Drogas , Historia Antigua , Humanos , Hipnóticos y Sedantes/química , Hipnóticos y Sedantes/aislamiento & purificación , Hipnóticos y Sedantes/toxicidad , Medicina Ayurvédica/historia , Medicina Ayurvédica/métodos , Medicina Tradicional China/historia , Medicina Tradicional China/métodos , Compuestos de Mercurio/química , Compuestos de Mercurio/aislamiento & purificación , Compuestos de Mercurio/toxicidad , Ratones , Nootrópicos/química , Nootrópicos/aislamiento & purificación , Nootrópicos/toxicidad , Agitación Psicomotora/fisiopatología , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Pruebas de ToxicidadRESUMEN
Pharmaceuticals which originally were designed to treat people with neurological and psychiatric conditions, e.g. Alzheimer's disease or attention deficit hyperactivity disorder (ADHD), are nowadays often misused by students as a 'brain doping' substances. These substances are known as nootropic drugs, smart drugs or cognitive enhancers, as they increase memory, attention and concentration of healthy individuals. Since they are easily available illicitly, their consumption is observed to be growing. Currently, these pharmaceuticals started gaining researchers' attention, especially since they have been recently detected in wastewater, surface water and even drinking water. This review summarises the current state of knowledge on nootropic drugs in terms of their population use trends and ethics, occurrence in the environment and detection techniques, toxicity and removal methods, in example of methylphenidate, modafinil and piracetam - three most popular nootropics. It points out that the main sources of knowledge on cognitive enhancers illicit use are often inconsistent questionnaires, which are not supported by wastewater analysis to become more veracious. Simultaneously, the studies concerning toxicity and removal methods of nootropic drugs are still limited and in many cases environmentally irrelevant. Although the prescription rules has been subjected to more strict control in developed countries, regulatory frameworks with regard to their ecosystem occurrence are still lacking and should be introduced. Moreover, the use of environmentally relevant concentrations in toxicity studies should be a standard, leading to proper ecotoxicity risk assessment. Based on this review, it is recommended to routinely monitor nootropics and their metabolites in waste- and surface waters.
Asunto(s)
Contaminantes Ambientales/análisis , Nootrópicos/análisis , Trastorno por Déficit de Atención con Hiperactividad , Encéfalo , Contaminantes Ambientales/toxicidad , Humanos , Memoria , Metilfenidato/análisis , Metilfenidato/toxicidad , Modafinilo/análisis , Modafinilo/toxicidad , Nootrópicos/toxicidad , Piracetam/análisis , Piracetam/toxicidad , Aguas ResidualesRESUMEN
Alzheimer's disease (AD) is a chronic, fatal and complex neurodegenerative disorder, which is characterized by cholinergic system dysregulation, metal dyshomeostasis, amyloid-ß (Aß) aggregation, etc. Therefore in most cases, single-target or single-functional agents are insufficient to achieve the desirable effect against AD. Multi-Target-Directed Ligand (MTDL), which is rationally designed to simultaneously hit multiple targets to improve the pharmacological profiles, has been developed as a promising approach for drug discovery against AD. To identify the multifunctional agents for AD, we developed an innovative method to successfully conceal the metal chelator into acetylcholinesterase (AChE) inhibitor. Briefly, the "hidden" agents first cross the Blood Brain Barrier (BBB) to inhibit the function of AChE, and the metal chelator will then be released via the enzymatic hydrolysis by AChE. Therefore, the AChE inhibitor, in this case, is not only a single-target agent against AD, but also a carrier of the metal chelator. In this study a total of 14 quinoline derivatives were synthesized and biologically evaluated. Both in vitro and in vivo results demonstrated that compound 9b could cross the BBB efficiently, then release 8a, the metabolite of 9b, into brain. In vitro, 9b had a potent AChE inhibitory activity, while 8a displayed a significant metal ion chelating function, therefore in combination, both 9b and 8a exhibited a considerable inhibition of Aß aggregation, one of the observations that plays important roles in the pathogenesis of AD. The efficacy of 9b against AD was further investigated in both a zebrafish model and two different mice models.
Asunto(s)
Quelantes/farmacología , Inhibidores de la Colinesterasa/farmacología , Nootrópicos/farmacología , Quinolinas/farmacología , Acetilcolinesterasa/química , Acetilcolinesterasa/metabolismo , Péptidos beta-Amiloides/química , Animales , Barrera Hematoencefálica/metabolismo , Quelantes/síntesis química , Quelantes/farmacocinética , Quelantes/toxicidad , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/farmacocinética , Inhibidores de la Colinesterasa/toxicidad , Diseño de Fármacos , Canal de Potasio ERG1/antagonistas & inhibidores , Masculino , Ratones , Microsomas Hepáticos/metabolismo , Simulación del Acoplamiento Molecular , Estructura Molecular , Nootrópicos/síntesis química , Nootrópicos/farmacocinética , Nootrópicos/toxicidad , Fragmentos de Péptidos/química , Multimerización de Proteína/efectos de los fármacos , Quinolinas/síntesis química , Quinolinas/farmacocinética , Quinolinas/toxicidad , Ratas Sprague-Dawley , Relación Estructura-Actividad , Pez CebraRESUMEN
Based on the quantitative structure-activity relationship (QSAR), some novel p-aminobenzoic acid derivatives as promising cholinesterase enzyme inhibitors were designed, synthesized, characterized and evaluated to enhance learning and memory. The in vitro enzyme kinetic study of the synthesized compounds revealed the type of inhibition on the respective acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The in vivo studies of the synthesized compounds exhibited significant reversal of cognitive deficits in the animal models of amnesia as compared to standard drug donepezil. Further, the ex vivo studies in the specific brain regions like the hippocampus, hypothalamus, and prefrontal cortex regions also exhibited AChE inhibition comparable to standard donepezil. The in silico molecular docking and dynamics simulations studies of the most potent compound 22 revealed the consensual interactions at the active site pocket of the AChE.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Inhibidores de la Colinesterasa/uso terapéutico , Nootrópicos/uso terapéutico , para-Aminobenzoatos/uso terapéutico , Acetilcolinesterasa/química , Acetilcolinesterasa/metabolismo , Animales , Encéfalo/metabolismo , Butirilcolinesterasa/química , Butirilcolinesterasa/metabolismo , Dominio Catalítico , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/química , Inhibidores de la Colinesterasa/toxicidad , Diseño de Fármacos , Femenino , Cinética , Masculino , Memoria/efectos de los fármacos , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Estructura Molecular , Nootrópicos/síntesis química , Nootrópicos/química , Nootrópicos/toxicidad , Relación Estructura-Actividad Cuantitativa , Ratas , Semicarbazonas/síntesis química , Semicarbazonas/química , Semicarbazonas/uso terapéutico , Semicarbazonas/toxicidad , para-Aminobenzoatos/síntesis química , para-Aminobenzoatos/química , para-Aminobenzoatos/toxicidadAsunto(s)
Nootrópicos/administración & dosificación , Nootrópicos/toxicidad , Trastornos Relacionados con Sustancias , Tiazepinas/administración & dosificación , Tiazepinas/toxicidad , Adulto , Analgésicos/administración & dosificación , Analgésicos/toxicidad , Dolor de Espalda/tratamiento farmacológico , Humanos , MasculinoRESUMEN
BACKGROUND: 6-chlorotacrine is a cholinesterase inhibitor showing good inhibitory potential, even better than parent compound tacrine, in vitro. Despite tacrine scaffold is broadly used for design and synthesis of novel compounds with anti-Alzheimer's potential, no in vivo effects have been investigated so far. Thus, basic toxicological and behavioural evaluation has been carried out throughout this study. METHODS: Maximum tolerated dose (MTD) and median lethal dose (LD50) were assessed in BALB/c mice and Wistar rats. Behavioural effects were observed in rats performing the multiple T-maze test, the water maze test and the step-through passive avoidance test. All outcomes were compared with the effects of parent compound - tacrine. RESULTS: The toxicity of 6-chlorotacrine was increased compared to tacrine with MTD 6.0/5.0 mg.kg-1 (i.m., male/female mice), 6.0/5.0 mg.kg-1 (i.p., male/female rats) and LD50 9.0 mg.kg-1 (male rats). At MTD doses, no histopathological changes and blood biochemistry abnormalities were observed except decreased plasma creatinine levels. 6-chlorotacrine showed good effects in the reversal of quinuclidinyl benzilate-induced amnesia. Best results were achieved at the dose of 1.8 mg.kg-1 (20% LD50) in the water maze test; the pro-cognitive effect was stronger than that of tacrine (5.2 mg.kg-1, 20% LD50). Other doses tested (0.9 mg.kg-1 and 2.7 mg.kg-1) showed similar effects as tacrine in the water maze, multiple T-maze and passive avoidance test. CONCLUSION: Observed effects predetermined 6-chlorotacrine as a potent parent compound for the synthesis of novel multifactorial drugs intended to the treatment of Alzheimer's disease. Even though 6- chlorotacrine showed in vivo beneficial effect with no signs of toxicity, further tests on the field of biochemistry and pharmacology are essential to disclose the exact mechanism of action, safety evaluation and the metabolic fate of the compound after the repeated administration.
Asunto(s)
Inhibidores de la Colinesterasa/farmacología , Inhibidores de la Colinesterasa/toxicidad , Tacrina/análogos & derivados , Animales , Reacción de Prevención/efectos de los fármacos , Inhibidores de la Colinesterasa/química , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones Endogámicos BALB C , Nootrópicos/química , Nootrópicos/farmacología , Nootrópicos/toxicidad , Ratas Wistar , Tacrina/química , Tacrina/farmacología , Tacrina/toxicidadRESUMEN
CONTEXT: Alzheimer's disease (AD) is believed to develop due to deposition of ß-amyloid (Aß) peptide. Hence, efforts are being made to develop potent drug that target amyloid hypothesis. OBJECTIVE: The present study explores the effect of the seaweed Gelidiella acerosa (Forsskål) Feldmann & Hamel (Gelidiellaceae) against Aß 25-35 peptide in Swiss albino mice. MATERIALS AND METHODS: The animals were administered through intracerebroventricular (ICV) injection with the Aß 25-35 peptide (10 µg/10 µL/ICV site) on 21st day of the pretreatment of G. acerosa (whole plant) benzene extract (200 and 400 mg/kg bw). On day 30, animals were sacrificed and brain tissue homogenate was prepared. The activities of AChE, BuChE, b-secretase, MAO-B, and caspase-3 were determined, and Bax expression was assessed by Western blotting. RESULTS: Gelidiella acerosa benzene extract restored the level of antioxidant enzymes and prevented lipid and protein oxidation significantly (p < 0.05). The extract protected the mice from cholinergic deficit significantly (p < 0.05) by inhibiting the activities of AChE and BuChE, which was about 0.116 ± 0.0088 U/mg of protein and 0.011 ± 0.0014 U/mg of protein respectively, which was otherwise increased in peptide-treated group (0.155 ± 0.007 U/mg of protein and 0.015 ± 0.0012 U/mg of protein respectively). Interestingly, G. acerosa benzene extract inhibited ß-secretase and MAO-B activity. Reduction (p < 0.05) in level of caspase-3 activity and Bax expression suggests that G. acerosa protects the cells from apoptosis. DISCUSSION AND CONCLUSION: The results suggest that G. acerosa possesses excellent neuroprotective potential against peptide mediated toxicity under in vivo conditions.
Asunto(s)
Enfermedad de Alzheimer/prevención & control , Péptidos beta-Amiloides , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Trastornos de la Memoria/prevención & control , Memoria/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Nootrópicos/farmacología , Fragmentos de Péptidos , Algas Marinas/química , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/inducido químicamente , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/psicología , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Animales , Apoptosis/efectos de los fármacos , Encéfalo/enzimología , Encéfalo/patología , Encéfalo/fisiopatología , Butirilcolinesterasa/metabolismo , Caspasa 3/metabolismo , Modelos Animales de Enfermedad , Donepezilo , Reacción de Fuga/efectos de los fármacos , Proteínas Ligadas a GPI/metabolismo , Indanos/farmacología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Trastornos de la Memoria/inducido químicamente , Trastornos de la Memoria/metabolismo , Trastornos de la Memoria/psicología , Ratones , Monoaminooxidasa/metabolismo , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/toxicidad , Nootrópicos/aislamiento & purificación , Nootrópicos/toxicidad , Estrés Oxidativo/efectos de los fármacos , Piperidinas/farmacología , Carbonilación Proteica/efectos de los fármacos , Proteína X Asociada a bcl-2/metabolismoRESUMEN
Irreversible acetylcholinesterase (AChE) inhibition accumulates to high levels in the central nervous system (CNS) because AChE turnover in the brain is much slower than in peripheral tissues. As expected from this CNS selectivity, the irreversible AChE inhibitor methanesulfonyl fluoride (MSF) produces significant cognitive improvement in Alzheimer's disease patients without the gastrointestinal toxicity that plagues other AChE inhibitors. However, without dose-limiting gastrointestinal toxicity, one shortcoming of the prior human studies of MSF is that the upper limits of CNS AChE inhibition that might be tolerated could not be tested. Therefore, in this study, monkeys were treated with escalating intramuscular (IM) doses of MSF that culminated with several weeks of 1.5âmg/kg dosing, more than eight times the prior human clinical dose, still without signs of toxicity. Brain biopsies showed that â¼80% AChE inhibition had been produced and that the new synthesis of cortical AChE had a half-time (t1/2) of â¼12 days. A single IM dose of 1.5âmg/kg MSF produced â¼59% inhibition in cerebrospinal fluid (CSF) AChE as measured one day later. This corresponds to a peak of â¼80% inhibition in CSF AChE at the time of the injection, recovering with a t1/2 of 2.4 days. Computational analyses suggest that MSF at clinically relevant doses could theoretically produce a steady-state AChE inhibition between 65% and 85% in the CNS. These data suggest that the full therapeutic advantage of AChE inhibition therapy can be realized without interference from dose-limiting gastrointestinal toxicity if an irreversible inhibitor is employed.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Inhibidores de la Colinesterasa/administración & dosificación , Inhibidores de la Colinesterasa/toxicidad , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/enzimología , Animales , Encéfalo/enzimología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Eritrocitos/efectos de los fármacos , Eritrocitos/enzimología , Inyecciones Intramusculares , Macaca fascicularis , Masculino , Nootrópicos/administración & dosificación , Nootrópicos/toxicidad , Factores de TiempoRESUMEN
BACKGROUND: In recent years, 5-hydroxytryptamine subtype 6 receptor (5-HT6 receptor, 5- HT6R) has emerged as a promising therapeutic target for the treatment of neuropathological disorders, including Alzheimer's disease (AD) and schizophrenia. 5-HT6 receptors were hypothesized to be implicated in the processes of learning, memory, and cognition with 5-HT6R antagonists being effective in animal models of cognition and memory impairment. Several selective 5-HT6R ligands are currently undergoing clinical trials for treatment of AD. METHODS: We describe results of preclinical development of a novel and highly selective and potent 5- HT6R antagonist, AVN-322, as a clinical candidate for the treatment of AD to improve concurrent debilitation of memory and cognition in the AD patients, and schizophrenia as a substance with antipsychotic effect. In the manuscript, we present its in vitro and vivo efficacy, ADME, pharmacokinetics in animals and in humans, and toxicity. RESULTS: While having high binding affinity in medium picomolar range, the lead compound demonstrates substantially better selectivity index then the reference drug candidates currently being tested in clinical studies. AVN-322 showed high oral bioavailability and favorable blood-brain barrier (BBB) penetration. In vivo testing revealed its clear cognition enhancing effect. AVN-322 significantly restored both scopolamine- and MK-801-induced cognitive dysfunction and demonstrated antipsychotic potential. CONCLUSION: Taking into account its good safety profile and favorable pharmacokinetics, AVN-322 can be reasonably considered as a novel drug candidate for the treatment of neurological disorders such as AD and/or schizophrenia.
Asunto(s)
Compuestos Heterocíclicos con 3 Anillos/farmacología , Trastornos de la Memoria/tratamiento farmacológico , Nootrópicos/farmacología , Antagonistas de la Serotonina/farmacología , Administración Intravenosa , Administración Oral , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Antipsicóticos/farmacocinética , Antipsicóticos/farmacología , Antipsicóticos/toxicidad , Línea Celular Tumoral , Modelos Animales de Enfermedad , Perros , Evaluación Preclínica de Medicamentos , Femenino , Células HEK293 , Compuestos Heterocíclicos con 3 Anillos/farmacocinética , Compuestos Heterocíclicos con 3 Anillos/toxicidad , Humanos , Macaca mulatta , Masculino , Ratones , Nootrópicos/farmacocinética , Nootrópicos/toxicidad , Absorción Peritoneal , Ratas Sprague-Dawley , Ratas Wistar , Receptores de Serotonina/metabolismo , Esquizofrenia/tratamiento farmacológico , Antagonistas de la Serotonina/farmacocinética , Antagonistas de la Serotonina/toxicidadRESUMEN
BACKGROUND: The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of therapies focused on these targets might be effective. We have developed and assessed a new product, coded ASS234, a multipotent acetyl and butyrylcholinesterase/monoamine oxidase A-B inhibitor with a potent inhibitory effect on amyloid-ß aggregation as well as antioxidant and antiapoptotic properties. But there is a need to reliably correlate in vitro and in vivo drug release data. METHODS: We examined the effect of ASS234 on cognition in healthy adult C57BL/6J mice in a model of scopolamine-induced cognitive impairment that often accompanies normal and pathological aging. Also, in a characterized transgenic APPswe/PS1ΔE9 mouse model of Alzheimer disease, we examined the effects of short-term ASS234 treatment on plaque deposition and gliosis using immunohistochemistry. Toxicology of ASS234 was assessed using a quantitative high-throughput in vitro cytotoxicity screening assay following the MTT assay method in HepG2 liver cells. RESULTS: In vivo, ASS234 significantly decreased scopolamine-induced learning deficits in C57BL/6J mice. Also, reduction of amyloid plaque burden and gliosis in the cortex and hippocampus was assessed. In vitro, ASS234 exhibited lesser toxicity than donepezil and tacrine. LIMITATIONS: The study was conducted in male mice only. Although the Alzheimer disease model does not recapitulate all features of the human disease, it exhibits progressive monoaminergic neurodegeneration. CONCLUSION: ASS234 is a promising alternative drug of choice to treat the cognitive decline and neurodegeneration underlying Alzheimer disease.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Corteza Cerebral/efectos de los fármacos , Hipocampo/efectos de los fármacos , Indoles/administración & dosificación , Aprendizaje/efectos de los fármacos , Nootrópicos/administración & dosificación , Piperidinas/administración & dosificación , Enfermedad de Alzheimer/patología , Animales , Supervivencia Celular/efectos de los fármacos , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Donepezilo , Gliosis/tratamiento farmacológico , Gliosis/patología , Células Hep G2 , Hipocampo/metabolismo , Humanos , Indanos/toxicidad , Indoles/química , Indoles/toxicidad , Masculino , Ratones Endogámicos C57BL , Nootrópicos/química , Nootrópicos/toxicidad , Piperidinas/química , Piperidinas/toxicidad , Placa Amiloide/tratamiento farmacológico , Placa Amiloide/patología , Prueba de Estudio Conceptual , Reconocimiento en Psicología/efectos de los fármacos , Escopolamina , Tacrina/toxicidadRESUMEN
BACKGROUND AND PURPOSE: AMPA receptor positive allosteric modulators represent a potential therapeutic strategy to improve cognition in people with schizophrenia. These studies collectively constitute the preclinical pharmacology data package used to build confidence in the pharmacology of this molecule and enable a clinical trial application. EXPERIMENTAL APPROACH: [N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro 1H-inden-2-yl]-2-propanesulfonamide] (UoS12258) was profiled in a number of in vitro and in vivo studies to highlight its suitability as a novel therapeutic agent. KEY RESULTS: We demonstrated that UoS12258 is a selective, positive allosteric modulator of the AMPA receptor. At rat native hetero-oligomeric AMPA receptors, UoS12258 displayed a minimum effective concentration of approximately 10 nM in vitro and enhanced AMPA receptor-mediated synaptic transmission at an estimated free brain concentration of approximately 15 nM in vivo. UoS12258 reversed a delay-induced deficit in novel object recognition in rats after both acute and sub-chronic dosing. Sub-chronic dosing reduced the minimum effective dose from 0.3 to 0.03 mg·kg-1 . UoS12258 was also effective at improving performance in two other cognition models, passive avoidance in scopolamine-impaired rats and water maze learning and retention in aged rats. In side-effect profiling studies, UoS12258 did not produce significant changes in the maximal electroshock threshold test at doses below 10 mg·kg-1 . CONCLUSION AND IMPLICATIONS: We conclude that UoS12258 is a potent and selective AMPA receptor modulator exhibiting cognition enhancing properties in several rat behavioural models superior to other molecules that have previously entered clinical evaluation.
Asunto(s)
Conducta Animal/efectos de los fármacos , Indenos/farmacología , Nootrópicos/farmacología , Receptores AMPA/efectos de los fármacos , Sulfonamidas/farmacología , Regulación Alostérica/efectos de los fármacos , Animales , Reacción de Prevención/efectos de los fármacos , Cognición/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Electrochoque , Humanos , Indenos/administración & dosificación , Indenos/toxicidad , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Nootrópicos/administración & dosificación , Nootrópicos/toxicidad , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Receptores AMPA/metabolismo , Reconocimiento en Psicología/efectos de los fármacos , Escopolamina/toxicidad , Sulfonamidas/administración & dosificación , Sulfonamidas/toxicidadRESUMEN
BACKGROUND: Familial Alzheimer's disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio of longer to shorter forms of the amyloid beta (Aß) peptide. The therapeutic rationale of γ-secretase modulators (GSMs) for Alzheimer's disease is based on this genetic evidence as well as on enzyme kinetics measurements showing changes in the processivity of the γ-secretase complex. This analysis suggests that GSMs could potentially offset some of the effects of PS mutations on APP processing, thereby addressing the root cause of early onset FAD. Unfortunately, the field has generated few, if any, molecules with good central nervous system (CNS) drug-like properties to enable proof-of-mechanism studies. METHOD: We characterized the novel GSM FRM-36143 using multiple cellular assays to determine its in vitro potency and off-target activity as well as its potential to reverse the effect of PS mutations. We also tested its efficacy in vivo in wild-type mice and rats. RESULTS: FRM-36143 has much improved CNS drug-like properties compared to published GSMs. It has an in vitro EC50 for Aß42 of 35 nM in H4 cells, can reduce Aß42 to 58 % of the baseline in rat cerebrospinal fluid, and also increases the non-amyloidogenic peptides Aß37 and Aß38. It does not inhibit Notch processing, nor does it inhibit 24-dehydrocholesterol reductase (DHCR24) activity. Most interestingly, it can reverse the effects of presenilin mutations on APP processing in vitro. CONCLUSIONS: FRM-36143 possesses all the characteristics of a GSM in terms of Aß modulation Because FRM-36143 was able to reverse the effect of PS mutations, we suggest that targeting patients with this genetic defect would be the best approach at testing the efficacy of a GSM in the clinic. While the amyloid hypothesis is still being tested with ß-site APP-cleaving enzyme inhibitors and monoclonal antibodies in sporadic AD, we believe it is not a hypothesis for FAD. Since GSMs can correct the molecular defect caused by PS mutations, they have the promise to provide benefits to the patients when treated early enough in the course of the disease.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Compuestos Heterocíclicos de 4 o más Anillos/uso terapéutico , Nootrópicos/uso terapéutico , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Línea Celular Tumoral , Evaluación Preclínica de Medicamentos , Células HEK293 , Células HeLa , Compuestos Heterocíclicos de 4 o más Anillos/farmacocinética , Compuestos Heterocíclicos de 4 o más Anillos/toxicidad , Humanos , Masculino , Ratones , Ratones de la Cepa 129 , Mutación , Neocórtex/efectos de los fármacos , Neocórtex/metabolismo , Nootrópicos/farmacocinética , Nootrópicos/toxicidad , Presenilina-1/genética , Presenilina-1/metabolismo , Ratas WistarRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Achyranthes aspera (A. aspera) has been used as a brain tonic in folk medicine. Although, ethnic use of medicinal plant has been basis for drug discovery from medicinal plants, but the available in-silico tools can be useful to find novel pharmacological uses of medicinal plants beyond their ethnic use. AIM OF THE STUDY: To validate in-silico prediction for novel nootropic effect of A. aspera by employing battery of tests in mice. MATERIAL AND METHODS: Phytoconstituents of A. aspera reported in Dictionary of Natural Product were subjected to in-silico prediction using PASS and Pharmaexpert. The nootropic activity predicted for A. aspera was assessed using radial arm maze, passive shock avoidance and novel object recognition tests in mice. After behavioral evaluation animals were decapitated and their brains were collected and stored for estimation of glutamate levels and acetylcholinesterase activity. RESULTS: In-silico activity spectrum for majority of A. aspera phytoconstituents exhibited excellent prediction score for nootropic activity of this plant. A. aspera extract treatment significantly improved the learning and memory as evident by decreased working memory errors, reference memory errors and latency time in radial arm maze, step through latency in passive shock avoidance and increased recognition index in novel object recognition were observed, moreover significantly enhanced glutamate levels and reduced acetylcholinesterase activity in hippocampus and cortex were observed as compared to the saline treated group. CONCLUSION: In-silico and in-vivo results suggest that A. aspera plant may improve the learning and memory by modulating the brain glutamatergic and cholinergic neurotransmission.
Asunto(s)
Achyranthes , Nootrópicos/farmacología , Extractos Vegetales/farmacología , Acetilcolinesterasa/metabolismo , Animales , Reacción de Prevención/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Simulación por Computador , Femenino , Ácido Glutámico/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Masculino , Memoria/efectos de los fármacos , Ratones , Actividad Motora/efectos de los fármacos , Nootrópicos/toxicidad , Extractos Vegetales/toxicidad , Raíces de Plantas , Pruebas de Toxicidad AgudaRESUMEN
Novel 2,3-benzodiazepine and related isoquinoline derivatives, substituted at position 1 with a 2-benzothiophenyl moiety, were synthesized to produce compounds that potently inhibited the action of GABA on heterologously expressed GABAA receptors containing the alpha 5 subunit (GABAA α5), with no apparent affinity for the benzodiazepine site. Substitutions of the benzothiophene moiety at position 4 led to compounds with drug-like properties that were putative inhibitors of extra-synaptic GABAA α5 receptors and had substantial blood-brain barrier permeability. Initial characterization in vivo showed that 8-methyl-5-[4-(trifluoromethyl)-1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one was devoid of sedative, pro-convulsive or motor side-effects, and enhanced the performance of rats in the object recognition test. In summary, we have discovered a first-in-class GABA-site inhibitor of extra-synaptic GABAA α5 receptors that has promising drug-like properties and warrants further development.
Asunto(s)
Anticonvulsivantes/farmacología , Benzodiazepinas/farmacología , Antagonistas de Receptores de GABA-A/farmacología , Nootrópicos/farmacología , Receptores de GABA-A/efectos de los fármacos , Animales , Anticonvulsivantes/síntesis química , Anticonvulsivantes/metabolismo , Anticonvulsivantes/toxicidad , Conducta Animal/efectos de los fármacos , Benzodiazepinas/síntesis química , Benzodiazepinas/metabolismo , Benzodiazepinas/toxicidad , Barrera Hematoencefálica/metabolismo , Permeabilidad Capilar , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Antagonistas de Receptores de GABA-A/síntesis química , Antagonistas de Receptores de GABA-A/metabolismo , Antagonistas de Receptores de GABA-A/toxicidad , Células HEK293 , Humanos , Masculino , Ratones , Estructura Molecular , Actividad Motora/efectos de los fármacos , Nootrópicos/síntesis química , Nootrópicos/metabolismo , Nootrópicos/toxicidad , Pentilenotetrazol , Ratas Sprague-Dawley , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Reconocimiento en Psicología/efectos de los fármacos , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Relación Estructura-Actividad , Xenopus laevisRESUMEN
The α7 nicotinic acetylcholine receptor (nAChR) is a recognized drug target for dementias of aging and certain developmental disorders. Two selective and potent α7-nAChR agonists, winnowed from a list of 43 compounds characterized in a companion article (DOI: 10.1021/acschemneuro.5b00058), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (IND8) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (QND8), were evaluated for cognitive improvement in both short- and long-term memory. Tacrine, a centrally active acetylcholinesterase inhibitor, and PNU-282987, a congeneric α7 nAChR agonist, were employed as reference standards. Three behavioral tests, modified Y-maze, object recognition test (ORT), and water maze, were performed in scopolamine-induced amnesic mice. Intraperitoneal injection of these two compounds significantly improved the cognitive impairment in a modified Y-maze test (5 µmol/kg for IND8 and 10 µmol/kg for QND8), ORT (10 µmol/kg), and water maze test (25 µmol/kg). For delay induced memory deficit or natural memory loss in mice, IND8 and QND8 at 10 µmol/kg were able to enhance memory comparable to PNU-282987 when evaluated using ORT time delay model. Cognitive enhancement of IND8 and QND8 was mediated through α7-nAChRs as evidenced by its complete abolition after pretreatment with a selective α7-nAChR antagonist, methyllycaconitine. These data demonstrate that IND8 and QND8 and their congeners are potential candidates for treatment of cognitive disorders, and the substituted triazole series formed by cycloaddition of alkynes and azides warrant further preclinical optimization.
Asunto(s)
Trastornos de la Memoria/tratamiento farmacológico , Agonistas Nicotínicos/farmacología , Nootrópicos/farmacología , Receptor Nicotínico de Acetilcolina alfa 7/agonistas , Animales , Benzamidas/farmacología , Compuestos Bicíclicos con Puentes/farmacología , Inhibidores de la Colinesterasa/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Humanos , Inyecciones Intraperitoneales , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Trastornos de la Memoria/fisiopatología , Ratones Endogámicos ICR , Modelos Químicos , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacocinética , Agonistas Nicotínicos/toxicidad , Nootrópicos/química , Nootrópicos/farmacocinética , Nootrópicos/toxicidad , Reconocimiento en Psicología/efectos de los fármacos , Reconocimiento en Psicología/fisiología , Escopolamina , Tacrina/farmacología , Receptor Nicotínico de Acetilcolina alfa 7/metabolismoRESUMEN
Previous work by our laboratory has shown that tacrine can produce long-lasting reductions in cocaine-reinforced behavior, when administered to rats as daily intravenous infusions over four days. Tacrine causes dose-related liver toxicity in different species, and its manufacture for human use was recently discontinued. This study was conducted to further characterize its actions on cocaine reward. Cocaine-experienced animals that had no contact with drug over one week resumed self-administration at levels similar to their initial baseline. When tacrine was administered over four days which were preceded and followed by washout periods to allow elimination of cocaine and tacrine respectively, subsequent cocaine self-administration was attenuated by more than one-half. Tacrine administered at 10 mg/kg-day as a chronic infusion by osmotic pump did not modify cocaine-induced increases in locomotor activity or conditioned-place preference. In rats that exhibited persistent attenuation of cocaine-self-administration after receiving tacrine, cocaine-induced reinstatement was also attenuated. No changes in plasma measures of renal or hepatic function were observed in rats receiving tacrine. In conclusion, pretreatment with tacrine can decrease cocaine-motivated behavior measured by self-administration or reinstatement, but not conditioned-place preference. Reductions in cocaine self-administration following pretreatment with tacrine do not require direct interaction with cocaine and are not secondary to either liver or kidney toxicity.